

Table 1. Comparison of auxologic parameters in patients with EPP (n=23) and patients with NP (n=63) before (0), after 12 months (1) and 24 months (2) of the therapy with recombinant human growth hormone (rhGH). Results are presented as medians and ranges; *p <0.05

Period of follow-up	hSD	hSD-mpSD	BA/CA
0			
<i>EPP</i>	-3.96* (-7.06, -2.75)	-3.65* (-7.06, -1.21)	0.62* (0.27, 0.92)
<i>NP</i>	-3.15 (-4.9, -2.35)	-1.83 (-4.31,-0.28)	0.75(0.21, 0.71)
1			
<i>EPP</i>	-2.76 (-4.67, -0.7)	-2.23* (-5.18, -1.19)	0.66* (0.38, 0.93)
<i>NP</i>	-2.44 (-4.34, -1.33)	-1.11(-2.23,-0.12)	0.81 (0.44, 0.79)
2			
<i>EPP</i>	-2.27 (-3.3, -0.69)	-1.79* (-3.71, -1.21)	0.77* (0.61, 0.93)
<i>NP</i>	-1.8 (-3.58, -0.2)	-1.1 (-0.98, -0.07)	0.84 (0.79, 0.95)

EPP: ectopic posterior pituitary group; NP: normal pituitary group; hSD: number of standard deviations from the mean population height; hSD-mpSD: the difference of hSD from the mid-parental height; BA/CA: bone age delay index (ratio of the bone age and chronological age).